Royal Bank of Canada Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $15.00

Perspective Therapeutics (NYSE:CATX) had its target price decreased by research analysts at Royal Bank of Canada from $16.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

A number of other equities research analysts also recently issued reports on CATX. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday. Finally, Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX traded up $0.09 during trading on Thursday, reaching $2.36. 197,806 shares of the company traded hands, compared to its average volume of 988,087. Perspective Therapeutics has a 52 week low of $2.15 and a 52 week high of $19.05. The company’s 50 day moving average is $2.98 and its two-hundred day moving average is $6.54.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Perspective Therapeutics by 19.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after acquiring an additional 11,472 shares during the period. Velan Capital Investment Management LP bought a new position in Perspective Therapeutics during the 4th quarter worth $1,595,000. Squarepoint Ops LLC acquired a new position in Perspective Therapeutics during the 4th quarter worth about $626,000. Wexford Capital LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at about $64,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $484,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.